Amendment No. 4 to License Agreement between the Regents of The University of Michigan and OncoMed Pharmaceuticals,Inc.

Exhibit 10.4(E)

Amendment No. 4 to License Agreement between

the Regents of The University of Michigan and

OncoMed Pharmaceuticals, Inc.

The License Agreement dated as of January 5, 2001, as heretofore amended (the “License Agreement”), between the REGENTS OF THE UNIVERSITY OF MICHIGAN, a constitutional corporation of the State of Michigan (“Michigan”) and ONCOMED PHARMACEUTICALS, INC., a Delaware corporation having offices at 265 N. Whisman Road, Mountain View, CA 94043 (“Licensee”), is hereby amended as follows:

1. Without limiting the generality of the definition of “Licensed Patent(s)” set forth in Section 30.4 of the License Agreement, Licensed Patents comprise the list of patent applications, disclosures and OTT files set forth on Attachment B hereto, and Attachment B referenced in Section 30.4 of the License Agreement is hereby amended by substituting in full Attachment B hereto.

2. Michigan hereby deems any and all of the support obligations of Licensee of continued research in the laboratories of Dr. Wicha and Dr. Clarke relating to the Licensed Field as described in Section 4.6 of the License fully satisfied, and Michigan hereby agrees that Licensee is relieved of any and all obligations to provide any payment pursuant to Section 4 of Amendment No. 1 to the License Agreement for the twelve-month period from July 21, 2004 and for any twelve-month period thereafter.

3. The License Agreement, as amended by this Amendment No. 4, shall otherwise remain unaltered and in full force and effect.

4. This Amendment No. 4 may be executed in counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Amendment No. 4 by their duly authorized officers or representatives effective as of December 12, 2005.